Arvinas Growth, Revenue, Number of Employees and Funding
Revenue & Financials
- Arvinas's revenue is currently $1.3M per year.
- Arvinas received $55.0M in venture funding in April 2018.
- Arvinas's revenue per employee is $15765
- Arvinas's total funding is $235.9M.
- Arvinas has 85 Employees.
- Arvinas grew their employee count by 49% last year.
- Arvinas currently has 17 job openings.
What Is Arvinas?
Arvinas is a pharmaceutical company focused on developing new small molecules - known as PROTACs (PROteolysis TArgeting Chimeras) - aimed at degrading disease-causing cellular proteins via proteolysis. Based on innovative research conducted at Yale University by Dr. Craig Crews, Founder and Chief Scientific Advisor, the company is translating natural protein degradation approaches into novel drugs for the treatment of cancer and other diseases. The proprietary PROTAC-based drug paradigm induces protein degradation, rather than protein inhibition, using the ubiquitin proteasome system and offers the advantage of potentially targeting undruggable as well as druggable elements of the proteome. This greatly expands the ability to create drugs for many new, previously unapproachable targets. For more information, visit www.arvinas.com.keywords:Biotechnology,Healthcare,Marketing,Pharmaceuticals
Number of Employees
Employee Growth %
|Name||Revenue||Number of Employees||Employee Growth||Total Funding|
Arvinas, Inc. (:ARVN) has been in the news after the price of the stock hit $16.67 at the conclusion of the most recent close. The stock is traded
Since Arvinas Holding Company LLC (NASDAQ:ARVN) and Cytori Therapeutics Inc. (NASDAQ:CYTX) are part of the Biotechnology industry,
Shares of Arvinas Inc. (ARVN) are nearing some key technical levels as the Rank Correlation indicator has trending higher over the past few
|2015-10-22||$41.6M||B||RA Capital Management||Article|
Arvinas Executive Hires
|2014-02-12||Jim Winkler||Chief Scientific Officer||Article|
|2015-09-24||Robert Kleinfield||Chief Development Officer||Article|
|2016-03-03||Angela Shen||Chief Medical Officer||Article|
|2017-01-06||John Houston||President of Research and Development and Chief Scientific Officer||Article|
|2017-09-21||John Houston||president and chief executive officer||Article|